New Integrase Inhibitor Tivicay (Dolutegravir) Approved for Treatment of HIV by FDA
August 13, 2013
On Aug. 12, Tivicay (dolutegravir) was approved as a first-line and second-line HIV treatment option, according to a news release by the U.S. Food and Drug Administration (FDA). Tivicay is an integrase inhibitor taken as a once-daily pill.
According to the FDA release:
Paul Sax, M.D., also wrote about Tivicay's approval, highlighting some of the strong results from clinical trials, including its non-inferiority to raltegravir (Isentress) and superior results over efavirenz/tenofovir/emtricitabine (Atripla).
However, he noted that this might be "the end of a remarkable stretch of HIV drug development, one that started in 2006 with darunavir, then marched through with maraviroc, raltegravir, etravirine, rilpivirine, and elvitegravir. The availability of these drugs, now with dolutegravir, means that pretty much anyone who takes their medications will achieve virologic suppression. Because after the tweak of tenofovir -- TAF -- what's next?"
Warren Tong is the research editor for TheBody.com and TheBodyPRO.com.
Follow Warren on Twitter: @WarrenAtTheBody.
Copyright © 2013 Remedy Health Media, LLC. All rights reserved.
This article was provided by TheBodyPRO.com.
Add Your Comment:
(Please note: Your name and comment will be public, and may even show up in
Internet search results. Be careful when providing personal information! Before
adding your comment, please read TheBody.com's Comment Policy.)